Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
B

BIIB

Nasdaq

BIOGEN INC.

Latest disclosureOctober 5, 2026
Insider score Why 0?
0/ 100
Qualifying buys · 30d
$0

0 purchases · 2 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 24

Limited filing history
All24Buying0Selling2Other22
Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

22 of 24 trades · April 1, 2026 – October 2, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 20 trades on this page.

Exercise or conversion

Sean Godbout

Chief Accounting Officer

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded October 2, 2026Filed October 5, 2026SEC filing
Tax or exercise withholding

Sean Godbout

Chief Accounting Officer

Common Stock

Value context
$1.76K
Reported price
$219.88 / share
Traded October 2, 2026Filed October 5, 2026SEC filing
Award disclosed

Sean Godbout

Chief Accounting Officer

Restricted Stock Unit

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded October 1, 2026Filed October 5, 2026SEC filing
Exercise or conversion

Sean Godbout

Chief Accounting Officer

Restricted Stock Unit

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$0.00 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded October 2, 2026Filed October 5, 2026SEC filing
Award disclosed

Michael Parini

Chief Legal Officer

Restricted Stock Unit

Derivative security · not the ordinary share price.

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded September 1, 2026Filed September 3, 2026SEC filing
Award disclosed

William A. Hawkins

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Stephen A. Sherwin

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Eric K. Rowinsky

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Jesus B. Mantas

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Susan Langer

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Monish D. Patolawala

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Exercise or conversion

Menelas N. Pangalos

Director

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Menelas N. Pangalos

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Exercise or conversion

Menelas N. Pangalos

Director

Restricted Stock Unit

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$0.00 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Lloyd Minor

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Award disclosed

Maria C. Freire

Director

Common Stock

Value context
Non-cash award
Reported price
Award · no purchase price
Understand this price

The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.

Traded June 9, 2026Filed June 11, 2026SEC filing
Exercise or conversion

Adam Keeney

Head of Corporate Development

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded May 1, 2026Filed May 5, 2026SEC filing
Tax or exercise withholding

Adam Keeney

Head of Corporate Development

Common Stock

Value context
$85.11K
Reported price
$187.06 / share
Traded May 1, 2026Filed May 5, 2026SEC filing
Exercise or conversion

Adam Keeney

Head of Corporate Development

Restricted Stock Unit

Derivative security · not the ordinary share price.

Value context
Not a separate purchase
Exercise / conversion price
$0.00 exercise / conversion price
Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Traded May 1, 2026Filed May 5, 2026SEC filing
Exercise or conversion

Sean Godbout

Chief Accounting Officer

Common Stock

Value context
Not established
Reported price
$0 reported · see filing
Understand this price

The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.

Traded April 1, 2026Filed April 3, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
Chief Accounting OfficerCommon StockOption exercise or conversion27$0 reported · see filingNot establishedOct 2Filed Oct 5 · 3d laterSEC filing
Chief Accounting OfficerCommon StockExercise-price or tax withholding8$219.88 / share$1.76KOct 2Filed Oct 5 · 3d laterSEC filing
Chief Accounting OfficerRestricted Stock UnitGrant or awardDerivative units985Award · no purchase priceNon-cash awardOct 1Filed Oct 5 · 4d laterSEC filing
Chief Accounting OfficerRestricted Stock UnitOption exercise or conversionDerivative units27$0.00 exercise / conversion priceNot a separate purchaseOct 2Filed Oct 5 · 3d laterSEC filing
Chief Legal OfficerRestricted Stock UnitGrant or awardDerivative units7,405Award · no purchase priceNon-cash awardSep 1Filed Sep 3 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockOption exercise or conversion2,370$0 reported · see filingNot establishedJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorRestricted Stock UnitOption exercise or conversionDerivative units2,370$0.00 exercise / conversion priceNot a separate purchaseJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award1,505Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
DirectorCommon StockGrant or award2,005Award · no purchase priceNon-cash awardJun 9Filed Jun 11 · 2d laterSEC filing
Head of Corporate DevelopmentCommon StockOption exercise or conversion939$0 reported · see filingNot establishedMay 1Filed May 5 · 4d laterSEC filing
Head of Corporate DevelopmentCommon StockExercise-price or tax withholding455$187.06 / share$85.11KMay 1Filed May 5 · 4d laterSEC filing
Head of Corporate DevelopmentRestricted Stock UnitOption exercise or conversionDerivative units939$0.00 exercise / conversion priceNot a separate purchaseMay 1Filed May 5 · 4d laterSEC filing
Chief Accounting OfficerCommon StockOption exercise or conversion181$0 reported · see filingNot establishedApr 1Filed Apr 3 · 2d laterSEC filing

Showing the latest 20 of 22 trades. Show all 22 trades

Congress transactions 8

All Congress filings
Sale disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a sale for the member.

Kevin Hern official portraitKevin HernReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
August 18, 2026
Filed September 1, 2026 · 14d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
March 27, 2026
Filed July 21, 2026 · 116d laterOriginal report
Sale disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a sale for the member.

Maria Elvira Salazar official portraitMaria Elvira SalazarReporting House member
Reported amount
$15,001 – $50,000Reported range; exact amount not disclosed.
Trade date
June 2, 2026
Filed July 7, 2026 · 35d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a purchase for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
June 5, 2026
Filed July 2, 2026 · 27d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a purchase for the member.

Maria Elvira Salazar official portraitMaria Elvira SalazarReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
May 12, 2026
Filed June 8, 2026 · 27d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a purchase for the member.

Maria Elvira Salazar official portraitMaria Elvira SalazarReporting House member
Reported amount
$50,001 – $100,000Reported range; exact amount not disclosed.
Trade date
May 11, 2026
Filed June 8, 2026 · 28d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a purchase for the member.

Maria Elvira Salazar official portraitMaria Elvira SalazarReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
May 11, 2026
Filed June 8, 2026 · 28d laterOriginal report
Purchase disclosed

Biogen Inc. - Common Stock (BIIB) · Stock

The filing reports a purchase for the member.

Gilbert Cisneros official portraitGilbert CisnerosReporting House member
Reported amount
$1,001 – $15,000Reported range; exact amount not disclosed.
Trade date
January 30, 2026
Filed February 13, 2026 · 14d laterOriginal report
Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage
Source
SEC EDGAR · Form 4
Issuer CIK
0000875045
Latest public acceptance
Oct 5, 2026, 09:00 PM UTC
Score calculated
Oct 8, 2026, 12:04 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.